

# CITATION REPORT

List of articles citing

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

DOI: 10.2337/diacare.28.5.1083  
Diabetes Care, 2005, 28, 1083-91.

**Source:** <https://exaly.com/paper-pdf/38787372/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1090	Drugs used in diabetes mellitus. 83-92		
1089	Proglucagon-derived peptides: mechanisms of action and therapeutic potential. <b>2005</b> , 20, 357-65		61
1088	Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. <b>2005</b> , 143, 559-69		628
1087	New sources of pancreatic beta-cells. <b>2005</b> , 23, 857-61		346
1086	Exenatide. <b>2005</b> , 4, 713-4		76
1085	Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. <b>2005</b> , 5, 346-52		6
1084	Drugs on the horizon for diabetes. <b>2005</b> , 5, 353-9		43
1083	Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes. <b>2005</b> , 22, 171-179		4
1082	Exenatide Injection. <b>2005</b> , 40, 994-1003		
1081	GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes. <b>2005</b> , 5, 485-497		2
1080	The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes. <b>2005</b> , 5, 227-235		3
1079	Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2005</b> , 28, 1092-100	14.6	1231
1078	Biologic actions and therapeutic potential of the proglucagon-derived peptides. <b>2005</b> , 1, 22-31		171
1077	Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. <b>2005</b> , 7, 467-77		77
1076	Investigational agents that protect pancreatic islet beta-cells from failure. <b>2005</b> , 14, 1241-50		6
1075	Medications associated with weight gain. <b>2005</b> , 39, 2046-55		53
1074	Exenatide. <b>2005</b> , 65, 1681-92; discussion 1693-5		51

1073	Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. <b>2005</b> , 4, 361-70	55
1072	Opinion and Evidence for Treatments in Endocrine Disorders. <b>2005</b> , 4, 323-330	
1071	Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide. <b>2006</b> , 32, 693-712	13
1070	Therapeutic approaches to preserve islet mass in type 2 diabetes. <b>2006</b> , 57, 265-81	124
1069	Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 1963-72	14.6 935
1068	Recent evidence of sustained benefit with exenatide in Type 2 diabetes. <b>2006</b> , 7, 2003-6	5
1067	Glycemic control in the metabolic syndrome and implications in preventing cardiovascular disease. <b>2006</b> , 4, 315-27	3
1066	Is exenatide advancing the treatment of type 2 diabetes?. <b>2006</b> , 7, 109-12	2
1065	Pharmacotherapies for diabetes management: an update for the practicing clinician. <b>2006</b> , 18, 379-89	3
1064	Tight control of hyperglycemia in type 2 diabetes mellitus. <b>2006</b> , 1, 166-172	8
1063	GLP-1: a new approach for type 2 diabetes therapy. <b>2006</b> , 74, S152-S155	19
1062	The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. <b>2006</b> , 368, 1696-705	2861
1061	[New approaches in obesity treatment: the gastrointestinal tract as an endocrine organ]. <b>2006</b> , 127, 300-5	1
1060	Diabetes: assessing the pipeline. <b>2006</b> , 7, 43-9	11
1059	Incretin-based therapies for type 2 diabetes: clinical utility. <b>2006</b> , 35 Suppl 1, 12-6; discussion 17-19	2
1058	The application of evidence-based principles of care in older persons (issue 3): management of diabetes mellitus. <b>2006</b> , 7, 234-40	29
1057	Hiperglucemia posprandial: importancia y tratamiento. <b>2006</b> , 53, 137-142	
1056	Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. <b>2006</b> , 4, 80	58

1055	Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. <b>2006</b> , 19, 612-20		31
1054	Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. <b>2006</b> , 281, 1159-68		167
1053	Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. <b>2006</b> , 28, 55-72		237
1052	Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. <b>2006</b> , 28, 652-65		70
1051	The biology of incretin hormones. <b>2006</b> , 3, 153-65		1583
1050	Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. <b>2006</b> , 346, 1067-74		82
1049	Immunogenicity of xenopeptide hormone therapies. <i>Peptides</i> , <b>2006</b> , 27, 1902-10	3.8	20
1048	Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience. <b>2006</b> , 12, 726-35		26
1047	Is exenatide a useful addition to diabetes therapy?. <i>Endocrine Practice</i> , <b>2006</b> , 12, 307-14	3.2	4
1046	Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. <i>Endocrine Practice</i> , <b>2006</b> , 12 Suppl 1, 142-7	3.2	12
1045	What are incretins, and how will they influence the management of type 2 diabetes?. <b>2006</b> , 12, S2-12; quiz S14-6		4
1044	Exenatide: a novel approach for treatment of type 2 diabetes. <b>2006</b> , 99, 1271-9		12
1043	Applying science to drug discovery. <b>2006</b> , 34, 238-242		3
1042	Applying science to drug discovery. <b>2006</b> , 34, 238-42		4
1041	Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. <b>2006</b> , 19, 281-4		55
1040	Addition of insulin to oral therapy in patients with type 2 diabetes. <b>2006</b> , 331, 257-63		17
1039	Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea. <b>2006</b> , 2006, 1-4		
1038	Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. <b>2006</b> , 46, 1179-87		42

1037 Obesity and type 2 diabetes mellitus in adolescents: what is new?. **2006**, 13, 111-118

1036 Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus. **2006**, 14, 205-11

20

1035 Current World Literature. **2006**, 13, 377-401

1034 Exenatide: from the Gila monster to the pharmacy. **2006**, 46, 44-52; quiz 53-5

31

1033 Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. **2006**, 8, 419-28

180

1032 Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. **2006**, 8, 436-47

360

1031 Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. **2006**, 23, 240-5

39

1030 Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes. **2006**, 23 Suppl 1, 14-9

5

1029 DPP-4 inhibitors and their potential role in the management of type 2 diabetes. **2006**, 60, 1454-70

253

1028 Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. **2006**, 60, 1654-61

40

1027 Managing older adults with diabetes. **2006**, 18, 309-17

12

1026 Gut hormones and the regulation of energy homeostasis. **2006**, 444, 854-9

560

1025 [Pharmacotherapy of obesity]. **2006**, 35, 500-4

1024 Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. **2006**, 49, 253-60

171

1023 Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. **2006**, 49, 1711-21

303

1022 What to inject when oral agents fail?. **2006**, 6, 341-3

1021 How do different GLP-1 mimetics differ in their actions?. **2006**, 6, 365-72

4

1020 Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. **2006**, 26, 360-74

27

1019	New and emerging strategies for reducing cardiometabolic risk factors. <b>2006</b> , 26, 13S-31S; quiz 43S-45S	9
1018	Evaluating and treating cardiometabolic risk factors: a case discussion. <b>2006</b> , 26, 32S-41S	
1017	Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes. <b>2006</b> , 67, 666-676	3
1016	Management of type 2 diabetes: the role of incretin mimetics. <b>2006</b> , 67, 545-552	1
1015	Therapeutic applications of incretin mimetics for metabolic diseases: preclinical studies. <b>2006</b> , 67, 553-558	3
1014	Current literature in diabetes. <b>2006</b> , 22, i-xii	
1013	Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. <b>2006</b> , 22, 483-91	89
1012	Management of Type 2 diabetes: the role of incretin mimetics. <b>2006</b> , 7, 2095-105	24
1011	Strukturierte Adipositas therapie. <b>2006</b> , 21, 163-172	
1010	Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. <b>2006</b> , 38, 838-44	62
1009	Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. <b>2006</b> , 7, 1055-64	48
1008	Preventive Cardiology. <b>2006</b> ,	
1007	Challenges and strategies for moving patients to injectable medications. <b>2006</b> , 32 Suppl 2, 82S-90S	10
1006	Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. <b>2006</b> , 30, 1332-40	107
1005	The evidence for achieving glycemic control with incretin mimetics. <b>2006</b> , 32 Suppl 2, 72S-81S	2
1004	Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. <i>Diabetes Care</i> , <b>2006</b> , 29, 435-49	14.6 87
1003	Review: Pharmacological approaches to reduce adiposity. <b>2006</b> , 6, 121-125	3
1002	Insulin signaling, glucose metabolism, and the angiotensin II signaling system: studies in Bartter's/Gitelman's syndromes. <i>Diabetes Care</i> , <b>2006</b> , 29, 469-71	14.6 23

1001	Exenatide (exendin-4)-induced pancreatitis: a case report. <i>Diabetes Care</i> , <b>2006</b> , 29, 471	14.6	104
1000	Exenatide: a new option for the treatment of type 2 diabetes. <b>2006</b> , 40, 1777-84		24
999	Clinical observations of exenatide treatment. <i>Diabetes Care</i> , <b>2006</b> , 29, 1984	14.6	25
998	Exenatide. <b>2006</b> , 63, 411-8		26
997	Use of Exenatide in Patients With Type 2 Diabetes. <b>2006</b> , 19, 181-186		4
996	Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. <b>2006</b> , 8, 385-96		39
995	The use of insulin glargine with gestational diabetes mellitus. <i>Diabetes Care</i> , <b>2006</b> , 29, 471-2	14.6	26
994	Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. <i>Diabetes Care</i> , <b>2006</b> , 29, 2371-7	14.6	23
993	Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice. <b>2006</b> , 55, 1562-70		17
992	Gut peptides in the regulation of food intake and energy homeostasis. <b>2006</b> , 27, 719-27		179
991	Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. <b>2006</b> , 1, 329-341		18
990	Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. <i>Diabetes Care</i> , <b>2007</b> , 30, 2767-72	14.6	86
989	Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!. <i>Diabetes Care</i> , <b>2007</b> , 30, 2972-3	14.6	21
988	Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. <b>2007</b> , 56, 438-43		93
987	Novel Approaches to Diabetes Treatment. <b>2007</b> , 140, 28-29		
986	DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. <b>2007</b> , 2, 567-572		
985	Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes. <b>2007</b> , 20, 159-165		44
984	The physiology of incretin hormones and the basis for DPP-4 inhibitors. <b>2007</b> , 33, 55-6, 60-2, 65-6		18

983	Themed Review: Lifestyle Interventions Across the Continuum of Type 2 Diabetes: Reducing the Risks of Diabetes. <b>2007</b> , 1, 327-334	5
982	Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. <b>2007</b> , 41, 51-60	35
981	Adapting the GLP-1-signaling system to the treatment of type 2 diabetes. <b>2007</b> , 3, 15-23	6
980	New Horizons in Diabetes Therapy. <b>2007</b> , 7, 49-55	3
979	GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. <b>2007</b> , 1, 193-201	
978	Diabetic gastroparesis. <b>2007</b> , 357, 418; author reply 419-20	2
977	Emerging Therapies for Type 2 Diabetes. <b>2007</b> , 2, 151-160	7
976	Indikationsgebiete inkretinbasierter Therapien: Analyse von Studienpopulation, Studiendesign und Effektivität in Exenatide- und DDP-4-Inhibitor-Studien. <b>2007</b> , 2, 315-320	
975	beta-cell failure in diabetes and preservation by clinical treatment. <b>2007</b> , 28, 187-218	556
974	[Recent examples for drug (developments) in primary, secondary and tertiary prevention]. <b>2007</b> , 132, 2212-6	
973	Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. <b>2007</b> , 23, 609-22	49
972	Safety and adverse effects associated with GLP-1 analogues. <b>2007</b> , 6, 417-22	6
971	Pharmacological treatment of the overweight patient. <b>2007</b> , 59, 151-84	131
970	Geriatric Diabetes. <b>2007</b> ,	2
969	Expanded Use of Exenatide in the Management of Type 2 Diabetes. <b>2007</b> , 20, 59-63	20
968	Case study 2: new insights: clinical pearls for using incretin mimetics in type 2 diabetes. <b>2007</b> , 33 Suppl 1, 14S-19S	2
967	Emerging Treatments for Patients With Type 2 Diabetes. <b>2007</b> , 33, 105S-110S	
966	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. <i>Endocrine Practice</i> , <b>2007</b> , 13 Suppl 1, 1-68	3-2 44 <sup>6</sup>



965	The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. <b>2007</b> , 28, 253-83	285
964	Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. <b>2007</b> , 298, 194-206	822
963	Achieving glycemic goals in type 2 diabetes. <i>Diabetes Care</i> , <b>2007</b> , 30, 174-80	14.6 10
962	Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes?. <b>2007</b> , 104, 689-90	25
961	Stem cells for the treatment of diabetes. <b>2007</b> , 54, 7-16	39
960	New drugs for the treatment of type 2 diabetes. <b>2007</b> , 68, 178-83	3
959	Glucagon-like peptide analogues for type 2 diabetes mellitus. <b>2007</b> ,	7
958	Incretins and their role in the management of diabetes. <b>2007</b> , 14, 269-76	21
957	Combination therapy with new targets in Type 2 diabetes: a review of available agents with a focus on pre-exercise adjustment. <b>2007</b> , 27, 193-201	10
956	Basal-prandial insulin: when is the right time to initiate treatment?. <b>2007</b> , 32, 24-9; quiz 29-30	
955	Bibliography. Current world literature. Diabetes and the endocrine pancreas. <b>2007</b> , 14, 170-96	
954	Using propensity scores subclassification to estimate effects of longitudinal treatments: an example using a new diabetes medication. <b>2007</b> , 45, S149-57	8
953	Current world literature. Lipid metabolism. <b>2007</b> , 18, 333-69	
952	Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. <b>2007</b> , 83, 24-8	110
951	A 74-year-old woman with diabetes. <b>2007</b> , 297, 196-204	12
950	Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. <b>2007</b> , 14, 98-107	56
949	Insulin treatment in managing type 2 diabetes: challenges and opportunities. <b>2007</b> , Suppl Initiating Insulin, 9-21	
948	Clinical management strategies for type 2 diabetes. <b>2007</b> , Suppl, 9-14	2

947	Biological activity of AC3174, a peptide analog of exendin-4. <b>2007</b> , 141, 113-9	32
946	Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. <b>2007</b> , 143, 64-8	61
945	Incretin-based therapies: mimetics versus protease inhibitors. <b>2007</b> , 18, 240-5	41
944	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. <b>2007</b> , 29, 139-53	235
943	Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy. <b>2007</b> , 29, 1784-94	13
942	Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. <b>2007</b> , 29, 2333-48	218
941	Medical therapy for obesity--current status and future hopes. <b>2007</b> , 91, 1225-53, xi	13
940	Gliptins. <b>2007</b> , 369, 269	
939	Stem/Progenitor cell sources of insulin-producing cells for the treatment of diabetes. <b>2007</b> , 13, 1399-412	64
938	Management of Type 2 Diabetes Mellitus with Basal-Prandial Insulin Therapy: A Case-Based Review. <b>2007</b> , 2, 118-126	1
937	Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes. <b>2007</b> , 1, 103-5	0
936	Incretin hormone mimetics and analogues in diabetes therapeutics. <b>2007</b> , 21, 497-516	86
935	Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. <b>2007</b> , 30, 1127-42	136
934	The physiology of glucagon-like peptide 1. <b>2007</b> , 87, 1409-39	2104
933	The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk. <b>2007</b> , 23, 1791-8	17
932	Clinical and economic evaluation of exenatide for formulary decisions. <b>2007</b> , 10, 529-537	6
931	Exenatide: a guide to its use as an adjunct to metformin and/or a sulfonylurea in patients with type 2 diabetes mellitus. <b>2007</b> , 23, 5-8	
930	Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs. <b>2007</b> , 7, 273-88	17

929	Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. <b>2007</b> , 23, 905-17	49
928	Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. <b>2007</b> , 23, 933-44	43
927	Le GLP-1 : de la physiologie à l'application thérapeutique. <b>2007</b> , 42, 199-206	
926	Update on diabetes in the elderly and the application of current therapeutics. <b>2007</b> , 8, 489-92	37
925	Metabolic syndrome and type 2 diabetes: can we stop the weight gain with diabetes?. <b>2007</b> , 91, 1107-23, ix	7
924	GLP 1 : effets biologiques et utilisation thérapeutique. <b>2007</b> , 68, 85-87	
923	L'Exébatide Quoi ? Comment ? Pour qui ?. <b>2007</b> , 1, 75-79	
922	Fonctions et régulation des différents sites de tissu adipeux (TA). <b>2007</b> , 68, 87-88	
921	The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. <b>2007</b> , 9, 317-26	29
920	[Incretins as new therapeutic targets of type 2 diabetes]. <b>2007</b> , 207, 352-64	0
919	Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). <b>2007</b> , 67, 935-54	72
918	Oral antidiabetic agents in type 2 diabetes. <b>2007</b> , 23, 945-52	68
917	Appetite regulation: an overview. <b>2007</b> , 17, 433-45	86
916	Exenatide. <b>2007</b> , 8, 2593-608	58
915	Drug treatment of the overweight patient. <b>2007</b> , 132, 2239-52	102
914	Biology of incretins: GLP-1 and GIP. <b>2007</b> , 132, 2131-57	2457
913	Gut hormones regulating appetite and metabolism. <b>2007</b> , 4, 147-151	2
912	When and how to restore $\beta$ cell function?. <b>2007</b> , 1303, 138-145	1

911	Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. <b>2007</b> , 23, 919-31		137
910	Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. <b>2007</b> , 50, 6126-32		178
909	Pharmacotherapeutic options for overweight adolescents. <b>2007</b> , 41, 1445-55		33
908	Diabetes/Syndrome X. <b>2007</b> , 417-458		3
907	The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. <b>2007</b> , 13, S2-16; quiz S17		8
906	Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide. <b>2007</b> , 2, 77-84		4
905	New therapeutic options for the management of diabetes. <b>2007</b> , 22, 45-56		5
904	A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo. <b>2007</b> , 57, 235-9		21
903	Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. <i>Endocrine Practice</i> , <b>2007</b> , 13, 260-8	3.2	57
902	Emerging treatments for patients with type 2 diabetes. <b>2007</b> , 33 Suppl 5, 105S-10S		1
901	The role of self-monitoring of blood glucose during the treatment of type 2 diabetes with medications targeting postprandial hyperglycemia. <b>2007</b> , 100, 1123-31		2
900	When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?. <b>2007</b> , 23, 257-64		91
899	Insulin-associated weight gain in diabetes--causes, effects and coping strategies. <b>2007</b> , 9, 799-812		351
898	Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. <b>2008</b> , 10, 18-33		16
897	Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <b>2007</b> , 9 Suppl 1, 23-31		54
896	Incretins and other peptides in the treatment of diabetes. <b>2007</b> , 24, 223-32		54
895	Effect of renal impairment on the pharmacokinetics of exenatide. <b>2007</b> , 64, 317-27		169
894	Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. <b>2007</b> , 61, 29-37		27

893	Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. <b>2007</b> , 61, 3-11		13
892	Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. <b>2007</b> , 61, 19-28		28
891	Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs. <b>2008</b> , 192, 117-25		6
890	A New Dawn for the Treatment of Type 2 Diabetes: Integrating Incretin Mimetics Into Clinical Practice. <b>2007</b> , 19, 1-24		1
889	A New Dawn for the Treatment of Type 2 Diabetes: Integrating Incretin Mimetics Into Clinical Practice. <b>2007</b> , 19, 1-24		
888	Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. <b>2007</b> , 27, 1163-80		39
887	Mechanisms of action of glucagon-like peptide 1 in the pancreas. <b>2007</b> , 113, 546-93		463
886	A Practical Guide for Aggressive Management of Type 2 Diabetes. <b>2007</b> , 3, 259-270		0
885	New therapies for diabetes. <b>2007</b> , 8, 58-63; discussion 64-5		6
884	Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. <i>Diabetes Care</i> , <b>2007</b> , 30, 1487-93	14.6	382
883	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <b>2007</b> , 50, 259-67		380
882	Pharmacotherapy for obesity. <b>2007</b> , 9, 454-62		10
881	GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. <b>2007</b> , 7, 340-7		36
880	Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity. <b>2007</b> , 7, 369-75		4
879	Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes. <b>2007</b> , 32, 311-6		3
878	Incretins: clinical physiology and bariatric surgery--correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure. <b>2007</b> , 17, 569-76		10
877	Inkretinmimetika und Inkretinverstärker. <b>2007</b> , 3, 387-398		1
876	Investigation of the Feasibility of an Amide-based Prodrug Under Physiological Conditions. <b>2008</b> , 14, 255-262		6

875	[New oral antidiabetic agents--clinical perspectives]. <b>2008</b> , 49, 495-501	4
874	Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. <b>2008</b> , 10, 55-60	32
873	Combination pharmacotherapy with incretins: what works best and when?. <b>2008</b> , 8, 361-7	
872	Glucagon-like peptide 1 based therapy for type 2 diabetes. <b>2008</b> , 4, 8-13	10
871	Purification and bioactivity of exendin-4, a peptide analogue of GLP-1, expressed in <i>Pichia pastoris</i> . <b>2008</b> , 30, 651-6	12
870	Common crossroads in diabetes management. <b>2008</b> , 2, 4	4
869	NICE gives rimonabant the green light. <b>2008</b> , 25, 302-304	
868	Impact of therapeutic advances on hypoglycaemia in type 2 diabetes. <b>2008</b> , 24, 257-85	11
867	Les incrétines. <b>2008</b> , 22, 59-65	
866	Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. <b>2008</b> , 356, 231-8	66
865	Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. <b>2008</b> , 24, 2943-52	321
864	Practical strategies to improve treatment of type 2 diabetes. <b>2008</b> , 20, 295-304	8
863	Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. <b>2008</b> , 11, 22-33	31
862	The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. <b>2008</b> , 11, 478-86	40
861	Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. <b>2008</b> , 10, 506-13	21
860	Beyond insulin replacement: addressing the additional needs of the diabetes patient. <b>2008</b> , 10 Suppl 2, 83-97	5
859	GLP-1: physiological effects and potential therapeutic applications. <b>2008</b> , 10, 994-1003	64
858	Glucagon-like peptide-1-based therapies: new developments and emerging data. <b>2008</b> , 10, 22-35	9

857	Hypoglycaemia in Type 2 diabetes. <b>2008</b> , 25, 245-54	372
856	The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. <b>2008</b> , 69, 737-44	49
855	Gastrointestinal peptides controlling body weight homeostasis. <b>2008</b> , 155, 481-95	17
854	Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin. <b>2008</b> , 28, 506-21	10
853	Improving Insulin Sensitivity: A Review of New Therapies. <b>2008</b> , 9, S28-S38	
852	Avances en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular. <b>2008</b> , 8, 62C-72C	1
851	Islet transplantation for brittle type 1 diabetes: the UIC protocol. <b>2008</b> , 8, 1250-61	142
850	Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions. <b>2008</b> , 118, 181-91	80
849	Therapeutic management of posttransplant diabetes mellitus. <b>2008</b> , 22, 116-24	9
848	Exenatide in Type 2 Diabetes: Indications and Initiation. <b>2008</b> , 347-352	
847	Clinical decisions. Management of type 2 diabetes. <b>2008</b> , 358, 293-7	29
846	The future of inhaled insulin and incretinmimetics in the management of diabetes. <b>2008</b> , 2, 59-61	2
845	Gut hormones as potential new targets for appetite regulation and the treatment of obesity. <b>2008</b> , 68, 147-63	19
844	Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. <b>2008</b> , 24, 2437-47	17
843	Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. <b>2008</b> , 5, 268-77	50
842	Novedades en terapia hipoglucemiante. Fármacos con acción incretina. <b>2008</b> , 55, 73-77	
841	Pancreatic Beta Cell in Health and Disease. <b>2008</b> ,	5
840	Medications for weight reduction. <b>2008</b> , 37, 923-42	19

839	Prise de poids et traitements antidiabétiques. <b>2008</b> , 2, 511-514	
838	Perspectives des incrétinomimétiques. <b>2008</b> , 69, 77-78	
837	Metformin therapy and clinical uses. <b>2008</b> , 5, 157-67	200
836	New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. <b>2008</b> , 25, 913-25	51
835	Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. <b>2008</b> , 18, 639-45	44
834	[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?]. <b>2008</b> , 29, 881-90	2
833	Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice. <b>2008</b> , 40, 1650-7	9
832	GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. <b>2008</b> , 367, 793-8	34
831	Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. <b>2008</b> , 30, 858-67	42
830	Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. <b>2008</b> , 30, 1448-60	294
829	Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials. <b>2008</b> , 80, e4-6	19
828	Incretin-based therapies in type 2 diabetes: a review of clinical results. <b>2008</b> , 82 Suppl 2, S102-7	21
827	Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. <b>2008</b> , 372, 1240-50	848
826	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <b>2008</b> , 24, 275-86	591
825	Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. <b>2008</b> , 24, 489-96	130
824	Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. <b>2008</b> , 34 Suppl 2, S78-90	20
823	DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?. <b>2008</b> , 34 Suppl 2, S91-5	20
822	Insulin resistance syndrome and glucose dysregulation in the elderly. <b>2008</b> , 24, 437-54, vi	2



821	Incretin-based Therapies for Type 2 Diabetes. <b>2008</b> , 32, 131-9	15
820	Exenatide: its position in the treatment of type 2 diabetes. <b>2008</b> , 69, 201-9	10
819	Anti-obesity drugs. <b>2008</b> , 9, 1339-50	15
818	Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. <b>2008</b> , 9, 1705-20	17
817	New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. <b>2008</b> , 117, 574-84	154
816	Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. <b>2008</b> , 24, 639-44	28
815	Analisi di costo-efficacia di exenatide versus insulina glargine nel trattamento dei pazienti diabetici di tipo 2 in fallimento secondario al doppio ipoglicemizzante orale. <b>2008</b> , 1, 21-30	2
814	The role of incretins in glucose homeostasis and diabetes treatment. <b>2008</b> , 60, 470-512	552
813	Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. <b>2008</b> , 24, 385-99	27
812	The Challenges and Opportunities of Managing Diabetes in Long-Term Care. <b>2008</b> , 9, 1-20	10
811	Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents. <b>2008</b> , 31, 371-9	12
810	Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. <b>2008</b> , 158, 773-84	33
809	Multidisciplinary Interventions: Mapping New Horizons in Diabetes Care. <b>2008</b> , 34, 78S-89S	4
808	Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. <b>2008</b> , 57, 1926-34	40
807	Incretin-based therapies in type 2 diabetes mellitus. <b>2008</b> , 93, 3703-16	159
806	The entero-insular axis: implications for human metabolism. <b>2008</b> , 46, 43-56	31
805	Can gut hormones control appetite and prevent obesity?. <i>Diabetes Care</i> , <b>2008</b> , 31 Suppl 2, S284-9	14.6 46
804	Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. <b>2008</b> , 29, 367-79	80

803	GLP-1 Agonists and Satiety. <b>2008</b> , 8, 311-316	2
802	Diabetes mellitus: considerations for dentistry. <b>2008</b> , 139 Suppl, 85-185	94
801	Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. <b>2008</b> , 10, 247-56	39
800	Diabetes and vascular disease. <b>2008</b> , 6, 127-38	13
799	New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. <b>2008</b> , 3 Suppl 2, S38-48	40
798	Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. <b>2008</b> , 61, 401-9	45
797	Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. <b>2008</b> , 57, 584-93	75
796	Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. <b>2008</b> , 2, 255-60	15
795	Three new drugs for type 2 diabetes. <b>2008</b> , 46, 49-52	4
794	Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia. <b>2008</b> , 46, 346-7	8
793	Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. <b>2008</b> , 34 Suppl 3, 66S-72S	3
792	More choices than ever before: emerging therapies for type 2 diabetes. <b>2008</b> , 34, 518-34	27
791	Recent advances in the management of type 2 diabetes mellitus: a review. <b>2008</b> , 84, 524-31	45
790	Pharmacology of GLP-1-based therapies. <b>2008</b> , 8, S10-S18	5
789	Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. <b>2008</b> , 42, 1541-51	22
788	Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. <b>2008</b> , 93, 2670-8	144
787	The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. <b>2008</b> , 120, 5-17	38
786	Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. <b>2008</b> , 17, 845-53	39

785	Verbesserung der Insulinsensitivität - Möglichkeiten und Grenzen der Pharmakotherapie. <b>2008</b> , 33, 62-69		
784	Inkretinbasierte Antidiabetika im Vergleich: GLP-1-Mimetika und DPP-IV-Inhibitoren. <b>2008</b> , 3, 234-240		
783	Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide. <b>2008</b> , 24, 3009-22		9
782	Hormone-based therapies in the regulation of fuel metabolism and body weight. <b>2008</b> , 8, 1733-47		11
781	Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. <b>2008</b> , 48, 1389-99		50
780	Exenatide: incretin therapy for patients with Type 2 diabetes mellitus. <b>2008</b> , 3, 671-690		4
779	Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. <b>2008</b> , 24, 401-17		12
778	The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. <b>2008</b> , 86, 36-45		71
777	Insulin, other hypoglycemic drugs, and glucagon. <b>2008</b> , 494-506		
776	Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. <b>2008</b> , 4, 101-9		40
775	Introductory chapter. 1-19		
774	Potential therapies to limit obesity. 302-319		
773	Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. <b>2008</b> , 11, 491-9		76
772	Multidisciplinary interventions: mapping new horizons in diabetes care. <b>2008</b> , 34 Suppl 4, 78S-89S		1
771	[New therapies for diabetes: beyond injectable insulin and oral antidiabetics]. <b>2008</b> , 54, 447-54		1
770	Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad. <b>2008</b> , 136,		3
769	Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. <i>Endocrine Practice</i> , <b>2008</b> , 14, 285-92	3.2	69
768	Exenatide use in the management of metabolic syndrome: a retrospective database study. <i>Endocrine Practice</i> , <b>2008</b> , 14, 993-9	3.2	20

767	Type I Allergy to Insulin: Case Report and Review of Localized and Systemic Reactions to Insulin. <b>2008</b> , 19, 52-58		6
766	The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes. <b>2008</b> , 14, S2-14; quiz 15-6		7
765	Managed care perspective on three new agents for type 2 diabetes. <b>2008</b> , 14, 363-80		29
764	Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. <b>2008</b> , 52, 1039-49		10
763	Can newer therapies delay the progression of type 2 diabetes mellitus?. <i>Endocrine Practice</i> , <b>2008</b> , 14, 625-38	3.2	21
762	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , Volume 2, 135-144	3.4	1
761	The use of incretin agents. <b>2009</b> , 20, 194-198		
760	Efficacy and safety of incretin based therapies: clinical trial data. <b>2009</b> , 49 Suppl 1, S30-40		54
759	Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. <b>2009</b> , 1, 1103-1119		1
758	Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. <b>2009</b> , 5, 683-98		9
757	Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , Volume 2, 23-30	3.4	1
756	Role and development of GLP-1 receptor agonists in the management of diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , Volume 2, 37-49	3.4	12
755	Potential of liraglutide in the treatment of patients with type 2 diabetes. <i>Vascular Health and Risk Management</i> , <b>2009</b> , 5, 199-211	4.4	51
754	Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes. <b>2009</b> , 1, CMT.S1085		1
753	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. <b>2009</b> , 10, 71-87		79
752	Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. <b>2009</b> , 49 Suppl 1, S16-29		101
751	Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. <b>2009</b> , 11, 353-9		23
750	Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. <b>2009</b> , 25, 65-75		73

749	Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. <i>Diabetes Care</i> , <b>2009</b> , 32, 1880-6	14.6	193
748	Exenatide improves hypertension in a rat model of the metabolic syndrome. <b>2009</b> , 7, 327-34		33
747	Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. <b>2009</b> , 76 Suppl 5, S28-38		48
746	Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. <b>2009</b> , 58, 2820-7		53
745	Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. <i>Diabetes Care</i> , <b>2009</b> , 32, 1237-43	14.6	100
744	Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis. <b>2009</b> , 104, 3112-4		4
743	Detection of asymptomatic ileal carcinoid tumors during ileal intubation at screening colonoscopy: a case series. <b>2009</b> , 104, 3114-5		11
742	Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes. <b>2009</b> , 9, 44-52		2
741	New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy. <b>2009</b> , 35, 731-4, 738-40, 742-4 passim		7
740	Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. <b>2009</b> , 160, 909-17		106
739	Expanding treatment options for type 2 diabetes: the old and the new. <b>2009</b> , 35 Suppl 1, 4S-11S		5
738	Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control. <b>2009</b> , 3, 964-70		36
737	Practical Use of Exenatide and Pramlintide for the Treatment of Type 2 Diabetes. <b>2009</b> , 22, 540-545		5
736	New therapeutic agents for diabetes mellitus: implications for anesthetic management. <b>2009</b> , 108, 1803-10		8
735	Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies. <b>2009</b> , 121, 16-25		34
734	Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. <b>2009</b> , 117, 522-57		74
733	Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge. <b>2009</b> , 37, 7-21		2
732	Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. <b>2009</b> , 121, 46-58		14

731	Beyond glyceic control: treating the entire type 2 diabetes disorder. <b>2009</b> , 121, 68-81	19
730	Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. <b>2009</b> , 10, 125-37	39
729	Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. <b>2009</b> , 4, 32-64	44
728	The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. <b>2009</b> , 121, 94-107	68
727	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <b>2009</b> , 22, 6-17	
726	Case Report. <b>2009</b> , 19, 119-121	3
725	Association of Exenatide With Liver Enzymes in Patients With Type 2 Diabetes. <b>2009</b> , 19, 114-115	2
724	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <b>2009</b> , 27, 4-16	18
723	Novel Approaches to the Treatment of Type 2 Diabetes. <b>2009</b> , 22, 320-332	3
722	An update on preventive and regenerative therapies in diabetes mellitus. <b>2009</b> , 121, 317-31	36
721	Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. <i>Pharmacology &amp; Therapeutics</i> , <b>2009</b> , 124, 113-38 <sup>13-9</sup>	143
720	Gut hormones: implications for the treatment of obesity. <i>Pharmacology &amp; Therapeutics</i> , <b>2009</b> , 124, 44-56 <sup>13-9</sup>	101
719	Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus. <b>2009</b> , 29, 43S-54S	15
718	Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. <b>2009</b> , 31, 806-15	34
717	Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. <b>2009</b> , 31, 1511-23	89
716	Diabetes mellitus and gastric emptying: questions and issues in clinical practice. <b>2009</b> , 25, 502-14	35
715	Pharmacotherapy in pediatric obesity: current agents and future directions. <b>2009</b> , 10, 205-14	13
714	The role of incretins in cardiovascular control. <b>2009</b> , 11, 18-22	21

713	Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. <b>2009</b> , 26, 217-29	11
712	Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <b>2009</b> , 52, 17-30	541
711	Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. <b>2009</b> , 52, 2046-55	674
710	Treatment options for type 2 diabetes:introducing the incretin-based therapies. <b>2009</b> , 26, 179-183ii	2
709	A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. <b>2009</b> , 8, 38	36
708	New treatments in type 2 diabetes: a focus on the incretin-based therapies. <b>2009</b> , 70, 343-53	36
707	Obesity treatment: novel peripheral targets. <b>2009</b> , 68, 830-43	49
706	Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. <b>2009</b> , 8, 369-85	323
705	Gut hormones and appetite control. <b>2009</b> , 15, 18-26	64
704	New developments in incretin-based therapies: the current state of the field. <b>2009</b> , 21 Suppl 1, 631-41	2
703	Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. <b>2009</b> , 63, 46-55	171
702	Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. <b>2009</b> , 63, 1154-60	35
701	Exenatide: a review from pharmacology to clinical practice. <b>2009</b> , 11, 544-56	86
700	Effect of antiobesity medications in patients with type 2 diabetes mellitus. <b>2009</b> , 11, 641-64	7
699	Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats. <b>2009</b> , 11, 884-90	6
698	The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies. <b>2009</b> , 11 Suppl 3, 1-3	1
697	Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes. <b>2009</b> , 11 Suppl 3, 4-10	2
696	The effects of glucagon-like peptide-1 on the beta cell. <b>2009</b> , 11 Suppl 3, 11-8	85

695	Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. <b>2009</b> , 11, 1122-30		28
694	Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. <b>2009</b> , 26, 722-8		92
693	Exenatide efficacy and safety: a systematic review. <b>2009</b> , 26, 837-46		68
692	Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. <b>2009</b> , 157, 1340-51		101
691	Exenatide once weekly for the treatment of type 2 diabetes. <b>2009</b> , 18, 359-67		35
690	One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. <i>Diabetes Care</i> , <b>2009</b> , 32, 762-8	14.6	327
689	Targeting the incretin system in type 2 diabetes mellitus. <b>2009</b> , 76, 244-56		3
688	Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives. <b>2009</b> , 52, 6889-96		39
687	Incretin-based therapies for type 2 diabetes mellitus. <b>2009</b> , 5, 262-9		510
686	Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. <i>Diabetes Care</i> , <b>2009</b> , 32, 84-90	14.6	882
685	Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. <b>2009</b> , 83, 69-76		74
684	GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes. <b>2009</b> , 85, 1-3		20
683	Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. <b>2009</b> , 20 Suppl 2, S329-39		33
682	Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. <b>2009</b> , 20 Suppl 2, S309-18		20
681	Preparation and PEGylation of exendin-4 peptide secreted from yeast <i>Pichia pastoris</i> . <b>2009</b> , 72, 412-7		17
680	Mining incretin hormone pathways for novel therapies. <b>2009</b> , 20, 280-6		29
679	The effect of exenatide re-exposure on safety and efficacy. <i>Peptides</i> , <b>2009</b> , 30, 1771-4	3.8	21
678	Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. <b>2009</b> , 122, S11-24		41



677	Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. <b>2009</b> , 122, S37-50		92
676	Pharmacologic management of the older patient with type 2 diabetes mellitus. <b>2009</b> , 7, 324-42		57
675	Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. <b>2009</b> , 25, 3049-57		39
674	Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?. <b>2009</b> , 23, 513-23		15
673	Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. <b>2009</b> , 23, 463-77		100
672	Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. <b>2009</b> , 75, 1272-1277		227
671	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2009</b> , 32, 193-203	14.6	2432
670	Diabetes medications and body weight. <b>2009</b> , 8, 573-84		93
669	Antidiabetic oral treatment in older people: does frailty matter?. <b>2009</b> , 26 Suppl 1, 53-62		26
668	Medications for obesity: mechanisms and applications. <b>2009</b> , 30, 525-38, ix		21
667	Pharmacotherapy of hyperglycemia. <b>2009</b> , 10, 2415-32		11
666	Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. <b>2009</b> , 10, 135-42		32
665	Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. <b>2009</b> , 3, 245-59		56
664	Appropriate, timely, and rational treatment of type 2 diabetes mellitus: Meeting the challenges of primary care. <b>2009</b> , 4, 144-157		4
663	Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. <b>2009</b> , 86 Suppl 1, S26-34		22
662	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). <b>2009</b> , 374, 39-47		1178
661	Synergistic weight loss and diabetes resolution with exenatide administration after laparoscopic gastric banding. <b>2009</b> , 5, 128-31		9
660	Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. <b>2009</b> , 18, 1495-503		62

659	Cardiovascular manifestations of insulin resistance. <b>2009</b> , 16, e14-28	10
658	Liraglutide: a new treatment for type 2 diabetes. <b>2009</b> , 45, 101-13	29
657	Sir David Cuthbertson Medal Lecture. Bariatric surgery as a model to study appetite control. <b>2009</b> , 68, 227-33	8
656	Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. <b>2009</b> , 56, 415-24	48
655	Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. <b>2009</b> , 56, 951-62	41
654	Incretin-Based Therapies in Patients with Type 2 Diabetes. <b>2010</b> , 5, 75-85	
653	Genetics of type 2 diabetes. <b>2010</b> , 13, 471-7	26
652	Liraglutide, a GLP-1 Analogue to Treat Diabetes. <b>2010</b> , 333-357	2
651	Managing type 2 diabetes in the primary care setting: beyond glucocentricity. <b>2010</b> , 340, 133-43	4
650	Weight management in type 2 diabetes mellitus. <b>2010</b> , 77, 533-48	12
649	New once-weekly formulation of exenatide for type 2 diabetes. <b>2010</b> , 11, 18-21	1
648	[Incretins: do they exert cardiovascular effects?]. <b>2010</b> , 35, 130-8	
647	[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus]. <b>2010</b> , 105, 163-75	
646	Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise. <b>2010</b> , 53, 139-43	19
645	The evolving place of incretin-based therapies in type 2 diabetes. <b>2010</b> , 25, 1207-17	25
644	Incretin therapy for type 2 diabetes mellitus. <b>2010</b> , 27, 881-94	1
643	Diabetes mellitus: new challenges and innovative therapies. <b>2010</b> , 1, 138-63	35
642	The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. <b>2010</b> , 144, 10-6	58

641	Exenatide and weight loss. <b>2010</b> , 26, 243-9	49
640	Glycaemic control in type 2 diabetes: targets and new therapies. <i>Pharmacology &amp; Therapeutics</i> , <b>2010</b> , 125, 328-61	13,9 130
639	Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. <b>2010</b> , 30, 609-24	43
638	Biological activity of EXf, a peptide analogue of exendin-4. <b>2010</b> , 628, 261-7	6
637	Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. <b>2010</b> , 628, 268-73	29
636	Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. <b>2010</b> , 10, 20	69
635	Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. <b>2010</b> , 9, 45	36
634	[GLP-1 mimetics in clinical studies. Treatment by activation of the GLP-1 receptor]. <b>2010</b> , 39, 120-5	
633	Exenatide associated renal failure. <b>2010</b> , 27, 232-234	7
632	Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?. <b>2010</b> , 64, 791-801	23
631	The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. <b>2010</b> , 64, 1402-14	31
630	Emerging treatment options for type 2 diabetes. <b>2010</b> , 70, 631-44	42
629	DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes. <b>2010</b> , 17, 171-80	25
628	Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. <b>2010</b> , 12, 267-87	63
627	Diabesity: therapeutic options. <b>2010</b> , 12, 463-73	81
626	Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. <b>2010</b> , 12, 341-7	78
625	A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. <b>2010</b> , 12, 1058-65	56
624	In support of an early polypharmacy approach to the treatment of type 2 diabetes. <b>2010</b> , 12, 929-40	20

623	Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. <b>2010</b> , 27, 309-17		158
622	Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. <b>2010</b> , 27, 1024-32		125
621	Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects. <b>2010</b> , 27, 1168-73		19
620	Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. <b>2010</b> , 6, 401-11		19
619	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , Volume 3, 165-172	3-4	
618	. <b>2010</b> ,		25
617	Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. <b>2010</b> , 4, 61-8		13
616	Diabetes:. 75-82		
615	Exenatide once weekly: clinical outcomes and patient satisfaction. <b>2010</b> , 4, 313-24		10
614	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , Volume 3, 227-242	3-4	3
613	Managing diabetes with new pharmaceutical agents. <b>2010</b> , 21, 634-638		
612	Tackling obesity: new therapeutic agents for assisted weight loss. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , Volume 3, 95-112	3-4	5
611	Pediatric Dosing and Body Size in Biotherapeutics. <b>2010</b> , 2, 389-418		25
610	The continuation of oral medications with the initiation of insulin therapy in type 2 diabetes: a review of the evidence. <b>2010</b> , 103, 58-65		13
609	Emerging role of GLP-1 receptor agonists in the treatment of obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , Volume 3, 263-273	3-4	8
608	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , Volume 3, 155-163	3-4	16
607	Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. <i>Vascular Health and Risk Management</i> , <b>2010</b> , 6, 541-8	4-4	80
606	Exenatide Use in the Management of Type 2 Diabetes Mellitus. <b>2010</b> , 3, 2554-2567		11

605	Exenatide-induced acute pancreatitis. <i>Endocrine Practice</i> , <b>2010</b> , 16, 80-3	3.2	37
604	A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus. <b>2010</b> , 2, CMT.S3489		
603	A practical Guide to Treatment with Liraglutide. <b>2010</b> , 2, CMT.S4148		1
602	Current developments in the treatment of diabetes: the incretin therapies. <b>2010</b> , 10, 21-30		1
601	Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. <b>2010</b> , 23, 334-9		153
600	Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. <b>2010</b> , 10, 801-6		46
599	The evolving world of GLP-1 agonist therapies for type 2 diabetes. <b>2010</b> , 1, 61-7		2
598	A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. <b>2010</b> , 86, 44-57		96
597	Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. <i>Diabetes Care</i> , <b>2010</b> , 33, 1300-3	14.6	153
596	Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus. <b>2010</b> , 67, 1326-36		9
595	Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. <b>2010</b> , 14, 1-248		99
594	Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. <i>Diabetes Care</i> , <b>2010</b> , 33, 1509-15	14.6	150
593	Weight Management in Overweight and Obese Patients with Type 2 Diabetes Mellitus. <b>2010</b> , 10, 274-283		12
592	Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention?. <b>2010</b> , 20, 723-36		73
591	Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial). <b>2010</b> , 11, 2269-71		8
590	The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. <b>2010</b> , 12, 11-24		29
589	Effectiveness of exenatide in Asian Indians in a clinical care setting. <b>2010</b> , 12, 613-8		4
588	Diabetes Treatment: Insulin and Incretins. <b>2010</b> , 28, 177-182		1

587	DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. <i>Diabetes Care</i> , <b>2010</b> , 33, 1255-61	14.6	274
586	Understanding GLP-1 analogs and enhancing patients success. <b>2010</b> , 36 Suppl 3, 44S-72S; quiz 73S-74S		14
585	The incretin system in the management of type 2 diabetes mellitus. <b>2010</b> , 10, 491-5		1
584	New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. <b>2010</b> , 122, 52-60		16
583	Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. <b>2010</b> , 298, H1096-102		126
582	Facilitation of $\beta$ cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac. <b>2010</b> , 2, 72-81		40
581	Can therapies that target the incretin system improve our ability to treat type 2 diabetes?. <b>2010</b> , 102, 511-23		5
580	Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation. <b>2010</b> , 42, 311-7		20
579	Excess health care costs of obesity in adults with diabetes mellitus: a claims data analysis. <b>2010</b> , 118, 496-504		14
578	Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. <b>2010</b> , 122, 172-83		7
577	How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation. <b>2010</b> , 122, 33-42		3
576	Incretin-based therapies for type 2 diabetes: a nurse's perspective. <b>2010</b> , 19, 1337-8, 1340-4		1
575	Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. <b>2010</b> , 122, 118-28		26
574	Blutzuckerkontrolle und Hypoglykämierisiko bei der Behandlung des Typ-2-Diabetes mit dem neuen GLP-1-Rezeptoragonisten Liraglutid. <b>2010</b> , 5, 287-292		
573	Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes. <b>2010</b> , 122, 7-15		90
572	Diabetic cardiomyopathy: signaling defects and therapeutic approaches. <b>2010</b> , 8, 373-91		45
571	Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes. <b>2010</b> , 3, 567-80		30
570	Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. <b>2010</b> , 85, S38-49		14

569	Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. <b>2010</b> , 85, S27-37	39
568	Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. <b>2010</b> , 50, 886-94	32
567	Non-Insulin Parenteral Therapies. <b>2010</b> , 478-493	1
566	Clinical experience with exenatide in a routine secondary care diabetes clinic. <b>2010</b> , 4, 57-60	3
565	Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. <b>2010</b> , 33, 87-100	19
564	Association of pancreatitis with glucagon-like peptide-1 agonist use. <b>2010</b> , 44, 904-9	61
563	Sulfonylureas uncouple glucose-dependence for GPR40-mediated enhancement of insulin secretion from INS-1E cells. <b>2010</b> , 315, 308-13	14
562	Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. <b>2010</b> , 36, 293-8	23
561	One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. <b>2010</b> , 36, 381-8	37
560	Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. <b>2010</b> , 123, 468.e9-17	75
559	Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. <b>2010</b> , 123, S19-27	52
558	Incretin-based therapies: review of current clinical trial data. <b>2010</b> , 123, S28-37	88
557	Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. <b>2010</b> , 123, S2-S10	26
556	Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. <b>2010</b> , 1, 24-36	10
555	Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. <b>2010</b> , 375, 2234-43	365
554	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. <b>2010</b> , 376, 431-9	503
553	Longacting exenatide in diabetes: DURATION-3. <b>2010</b> , 375, 2198-9	2
552	The incretin system and cardiometabolic disease. <b>2010</b> , 26, 87-95	10

551	Epac2-dependent rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1. <b>2010</b> , 84, 279-302	52
550	Analisi economica di exenatide rispetto a liraglutide nei pazienti con diabete di tipo 2: costo-efficacia e budget impact. <b>2010</b> , 3, 73-79	
549	Exenatide versus glibenclamide in patients with diabetes. <b>2010</b> , 12, 233-40	97
548	Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. <b>2011</b> , 27, 2335-42	14
547	Valutazione economica del trattamento con exenatide o sitagliptin di pazienti affetti da diabete tipo 2 in Italia. <b>2011</b> , 4, 1-6	2
546	Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies. <b>2011</b> , 13, 1063-9	20
545	Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. <b>2011</b> , 27, 531-40	4
544	Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. <b>2011</b> , 3, 217-236	1
543	Type 2 Diabetes in Adults. <b>2011</b> , 77-137	3
542	Incretin-based therapies and their future in Type 2 diabetes mellitus. <b>2011</b> , 8, 143-152	1
541	Add-on therapies to metformin for type 2 diabetes. <b>2011</b> , 12, 47-62	14
540	Medications for weight reduction. <b>2011</b> , 95, 989-1008	6
539	New treatments for type 2 diabetes in the UK - an evolving landscape. <b>2011</b> , 5, 1-7	
538	Emerging GLP-1 receptor agonists. <b>2011</b> , 16, 607-18	20
537	Drug-induced hypoglycaemia: an update. <b>2011</b> , 34, 21-45	50
536	Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. <b>2011</b> , 50, 65-74	103
535	Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. <b>2011</b> , 71, 1675-88	63
534	GLP-1 and energy balance: an integrated model of short-term and long-term control. <b>2011</b> , 7, 507-16	147



533	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. <b>2011,</b>	6
532	Pharmacological management of type 2 diabetes mellitus: an update. <b>2011, 7, 392-405</b>	54
531	Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. <b>2011, 124, S3-18</b>	220
530	Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?. <b>2011, 124, S19-34</b>	54
529	Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. <b>2011, 124, S35-53</b>	58
528	Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. <b>2011, 124, S54-61</b>	15
527	Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. <b>2011, 37, 477-88</b>	38
526	GLP-1 receptor agonists today. <b>2011, 93, 317-27</b>	17
525	Emerging therapies in the treatment of 'diabesity': beyond GLP-1. <b>2011, 32, 8-15</b>	32
524	GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated $\beta$ cell damage in Akita mice. <b>2011, 2, 104-10</b>	14
523	Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. <b>2011, 2, 210-7</b>	43
522	Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. <b>2011, 2, 448-56</b>	12
521	Incretin effect: GLP-1, GIP, DPP4. <b>2011, 93 Suppl 1, S32-6</b>	52
520	The Current Status of Exenatide Once Weekly. <b>2011, 3, CMT.S3083</b>	4
519	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. <i>Endocrine Practice</i> , <b>2011, 17 Suppl 2, 1-53</b>	3-2 329
518	Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus. <b>2011,</b>	
517	. <b>2011,</b>	1
516	GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies. <b>2011, 279-325</b>	

515 Unit 5. Antidiabetic treatment options. **2011**, 22, 1-8

514 Using Gene Expression Signatures to Dissect Insulin Resistance Subtypes. **2011**, 1

513 The results of prolonged action of GLP-1 on some metabolic parameters. **2011**, 59, 13-7 1

512 International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm. *Diabetes Management*, **2011**, 1, 175-189 0 12

511 Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. **2011**, 154, 672-9 104

510 Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. **2011**, 154, 103-12 405

509 Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. **2011**, 13, 99-117 30

508 Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. **2011**, 13, 302-12 104

507 The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. **2011**, 13, 418-25 71

506 Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit\*. **2011**, 13, 703-10 73

505 Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. **2011**, 12, 593-601 40

504 Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. **2011**, 163, 399-412 42

503 Update on incretin hormones. **2011**, 1243, E55-74 88

502 Antibodies in metabolic diseases. **2011**, 28, 530-7 10

501 Liraglutide: clinical pharmacology and considerations for therapy. **2011**, 31, 896-911 17

500 A review of diabetes treatment adherence and the association with clinical and economic outcomes. **2011**, 33, 74-109 280

499 Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. **2011**, 33, 408-24 22

498 Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. **2011**, 33, 528-76 39

497	Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. <b>2011</b> , 33, 665-78	47
496	Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. <b>2011</b> , 33, 1698-712	18
495	Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics. <b>2011</b> , 22, 625-32	45
494	Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. <b>2011</b> , 45, 850-60	45
493	Effects of glucose-lowering drugs on body weight in type 2 diabetes. <b>2011</b> , 22, 32-42	
492	Is the GLP-1 system a viable therapeutic target for weight reduction?. <b>2011</b> , 12, 187-95	15
491	[Anti-diabetic drugs. Weight reduction as a favourable side effect]. <b>2011</b> , 52, 451-2, 455-8, 460-1	4
490	Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. <b>2011</b> , 2, 162-77	10
489	Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. <b>2011</b> , 11, 9	56
488	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <b>2011</b> , 10, 22	124
487	Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb. <b>2011</b> , 13, 470-7	4
486	The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. <b>2011</b> , 27, 528-42	75
485	Potential use of exenatide for the treatment of obesity. <b>2011</b> , 20, 1717-22	9
484	Liraglutide for type 2 diabetes mellitus. <b>2011</b> , 11, 951-9	3
483	The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. <b>2011</b> , 123, 189-201	25
482	Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. <b>2011</b> , 39, 7-21	36
481	Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers. <b>2011</b> , 51, 165-72	15
480	Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. <b>2011</b> , 96, 1695-702	106

479	Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists. <i>Diabetes Care</i> , <b>2011</b> , 34 Suppl 2, S272-5	14.6	3
478	GLP-1 receptor agonists and HBA1c target of . <b>2011</b> , 27, 1519-28		37
477	Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. <b>2011</b> , 96, E1314-9		48
476	DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. <b>2011</b> , 96, 1301-10		346
475	Polypharmacy and renal failure. <b>2011</b> , 11, 150-152		1
474	Hypoglycaemia: current management and controversies. <b>2011</b> , 87, 298-306		35
473	Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. <b>2011</b> , 2011, 215764		85
472	From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. <b>2011</b> , 2011, 898913		15
471	The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus. <b>2011</b> , 4, 13-24		2
470	Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. <b>2011</b> , 24, 26-35		5
469	Incretin effects on $\beta$ -cell function, replication, and mass: the human perspective. <i>Diabetes Care</i> , <b>2011</b> , 34 Suppl 2, S258-63	14.6	71
468	Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials. <b>2011</b> , 1, 327-343		1
467	Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. <b>2011</b> , 13, 143-8		59
466	Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. <i>Diabetes Care</i> , <b>2011</b> , 34 Suppl 2, S279-84	14.6	235
465	Diabetes mellitus: new drugs for a new epidemic. <b>2011</b> , 107, 65-73		48
464	Management of Pediatric Obesity and Diabetes. <b>2011</b> ,		3
463	Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. <b>2011</b> , 123, 53-65		14
462	Fundamental Characterization Studies of Condensed Chemical Mechanical Polishing Waste Slurry. <b>2011</b> , 34, 615-620		

461	GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats. <b>2012</b> , 122, 375-84		23
460	Hypoglycemia in type 2 diabetes: current controversies and changing practices. <i>Frontiers in Endocrinology</i> , <b>2012</b> , 3, 66	5-7	10
459	Structural Insights into the Active Site of Human Sodium Dependent Glucose Co-Transporter 2: Homology Modelling, Molecular Docking, and 3D - QSAR Studies. <b>2012</b> , 65, 1314		18
458	Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. <b>2012</b> , 3, 185-201		4
457	What have we learned about the treatment of type 2 diabetes? The evolving paradigms. <b>2012</b> , 19, 449-64		2
456	Drug-drug interactions with glucagon-like peptide-1 receptor agonists. <b>2012</b> , 46, 710-7		17
455	Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. <b>2012</b> , 124, 21-32		33
454	Effects of exenatide in poorly controlled type 2 diabetes. <b>2012</b> , 105, 321-6		4
453	Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?. <b>2012</b> , 44, 338-49		7
452	Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany. <b>2012</b> , 15, 746-57		8
451	Glucose-dependent insulintropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulintropic peptide receptor-overexpressing adipocytes. <b>2012</b> , 26, 2383-93		36
450	Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. <i>Diabetes Care</i> , <b>2012</b> , 35, 4-11	14.6	161
449	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <b>2012</b> , 25, 154-171		22
448	GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. <b>2012</b> , 9, 95-108		67
447	A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1. <b>2012</b> , 6, 213-9		3
446	Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. <i>Diabetes Care</i> , <b>2012</b> , 35, 1986-93	14.6	50
445	Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. <b>2012</b> , 46, 812-21		13
444	Safety and tolerability of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. <b>2012</b> , 12, 6-16		1

443	Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. <b>2012</b> , 2012, 230624	28
442	Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. <b>2012</b> , 2012, 672658	61
441	FMCSA's medical review board: five years of progress in commercial driver medical examinations. <b>2012</b> , 54, 424-30	17
440	Determining predictors of response to exenatide in type 2 diabetes. <b>2012</b> , 52, 466-71	21
439	Exenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors. <b>2012</b> , 9, 23-38	
438	Recent advances in incretin-based therapies. <b>2012</b> , 77, 489-99	54
437	The cardiovascular effects of GLP-1 receptor agonists. <b>2012</b> , 30, e146-55	88
436	Exenatide as a novel weight loss modality in patients without diabetes. <b>2012</b> , 46, 1700-6	9
435	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. <b>2012</b> , 344, d7771	575
434	Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. <b>2012</b> , 82, 1066-73	44
433	Management of diabetes in primary care: individualisation of care. <b>2012</b> , 29, 331-334a	2
432	The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. <b>2012</b> , 14, 561-7	52
431	Impatto delle incretine sulla gestione del paziente diabetico: dati del monitoraggio antidiabetici AIFA. <b>2012</b> , 13, 210-215	
430	The role of the gut/brain axis in modulating food intake. <b>2012</b> , 63, 46-56	107
429	The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. <b>2012</b> , 62, 1916-27	185
428	GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K <sup>+</sup> channel. <b>2012</b> , 61, 2585-91	77
427	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. <b>2012</b> , 8, 728-42	744
426	Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes. <b>2012</b> , 36, 9-14	3

425	An overview of the pharmacokinetics, efficacy and safety of liraglutide. <b>2012</b> , 97, 27-42		53
424	Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry. <b>2012</b> , 12, 23		48
423	Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. <b>2012</b> , 12, 8		18
422	Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. <b>2012</b> , 4, 13		186
421	Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation. <b>2012</b> , 26, E471-84		28
420	Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. <b>2012</b> , 66, 1147-57		12
419	Exenatide plus metformin compared with metformin alone on $\beta$ cell function in patients with Type 2 diabetes. <b>2012</b> , 29, 1515-23		48
418	A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. <b>2012</b> , 13, 1451-67		21
417	Novel GLP-1 receptor agonists for diabetes. <b>2012</b> , 21, 45-57		54
416	Newer Diabetes Medications. <b>2012</b> , 375-417		
415	Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , <b>2012</b> , 35, 1364-79	14.6	2713
414	Alterations in energy balance following exenatide administration. <b>2012</b> , 37, 893-9		33
413	Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. <b>2012</b> , 34, 1892-908.e1		63
412	A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. <b>2012</b> , 98, 271-84		117
411	Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. <b>2012</b> , 7, 15-26		6
410	Prise en charge de l'hyperglycémie chez le patient diabétique de type 2 : une stratégie centrée sur le patient. <b>2012</b> , 6, III-XXV		2
409	Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro. <b>2012</b> , 153, 2208-22		52
408	An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists. <b>2012</b> , 14, 951-67		23

407	Reevaluating goals of insulin therapy: perspectives from large clinical trials. <b>2012</b> , 41, 41-56		6
406	Treatment with glucagon-like Peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor. <b>2012</b> , 78, 54-8		21
405	A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities. <b>2012</b> , 33, 148-54		24
404	Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. <b>2012</b> , 3, 6		8
403	Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. <i>Endocrine Practice</i> , <b>2012</b> , 18, 227-37	3.2	11
402	The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. <b>2012</b> , 15, 1-30		20
401	Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States. <i>Endocrine Practice</i> , <b>2012</b> , 18, 700-11	3.2	5
400	Incretin therapies for type 2 diabetes: what nurses need to know. <b>2012</b> , 10, 345-352		
399	Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2012</b> , 5, 29-41	3.4	33
398	Pharmacologic management of obesity. <b>2012</b> , 58, 140-3		5
397	Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice. <b>2012</b> , 29, 61-64		1
396	The effect of glucagon-like peptide 1 on cardiovascular risk. <b>2012</b> , 9, 209-22		117
395	Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. <i>Diabetes Care</i> , <b>2012</b> , 35, 683-9	14.6	80
394	A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. <b>2012</b> , 3, 1-16		5
393	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <b>2012</b> , 55, 1577-96		1108
392	Incretin-based therapies. <b>2012</b> , 4, 55-67		29
391	Using albumin to improve the therapeutic properties of diabetes treatments. <b>2012</b> , 14, 121-9		8
390	Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population. <b>2012</b> , 34, 1145-58		1



389	Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. <b>2012</b> , 34, 1221-36		47
388	Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. <b>2012</b> , 34, 1247-1258.e22		200
387	Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary. <b>2012</b> , 34, 1301-13		3
386	Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?. <b>2012</b> , 24 Suppl 1, 249-59		10
385	Impact of postprandial glycaemia on health and prevention of disease. <b>2012</b> , 13, 923-84		232
384	The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review. <b>2012</b> , 14, 387-98		13
383	GLP-1 based therapies: differential effects on fasting and postprandial glucose. <b>2012</b> , 14, 675-88		91
382	Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. <b>2012</b> , 14, 546-54		113
381	The design of the liraglutide clinical trial programme. <b>2012</b> , 14 Suppl 2, 4-12		8
380	Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. <b>2012</b> , 14 Suppl 2, 41-9		20
379	Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. <b>2012</b> , 4, 8		13
378	Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. <b>2012</b> , 14, 60-9		20
377	Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example. <b>2012</b> , 29, 306-18		13
376	Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. <i>Endocrine Practice</i> , <b>2012</b> , 18 Suppl 3, 6-26; quiz 27-8	3.2	6
375	Diabetes. <b>2013</b> ,		7
374	Lipids, CHOs, proteins: can all macronutrients put a 'brake' on eating?. <b>2013</b> , 120, 114-23		62
373	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. <b>2013</b> , 381, 117-24		397
372	Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. <b>2013</b> , 12, 48		15

371	Multilayer nanoparticles for sustained delivery of exenatide to treat type 2 diabetes mellitus. <b>2013</b> , 34, 8444-9	27
370	The Incretin Mimetics. <b>2013</b> , 20-32	
369	Complementing insulin therapy to achieve glycemic control. <b>2013</b> , 30, 557-76	28
368	[Management of type 2 diabetes: new or previous agents, how to choose?]. <b>2013</b> , 42, 861-70	3
367	Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. <b>2013</b> , 39, 485-96	59
366	Analyzing and Forecasting the Fusion Protein Market and Pipeline. <b>2013</b> , 25-37	
365	Complications of diabetes therapy. <b>2013</b> , 42, 947-70	16
364	The cardiovascular safety of incretin-based therapies: a review of the evidence. <b>2013</b> , 12, 130	33
363	Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE. <b>2013</b> , 4, 285-308	10
362	Incretin-based therapies: focus on effects beyond glycemic control alone. <b>2013</b> , 4, 221-38	12
361	Effect of chitosan on physicochemical properties of exenatide-loaded PLGA nanoparticles. <b>2013</b> , 43, 489-497	9
360	Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. <b>2013</b> , 37, 1391-8	65
359	Voltage-gated proton channels: molecular biology, physiology, and pathophysiology of the H(V) family. <b>2013</b> , 93, 599-652	152
358	Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. <b>2013</b> , 4, 182-9	11
357	Oral delivery of therapeutic protein/peptide for diabetes--future perspectives. <b>2013</b> , 440, 48-62	121
356	Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. <b>2013</b> , 15, 42-54	74
355	Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes. <b>2013</b> , 50, 39-45	24
354	Caractéristiques physiologiques et pharmacologiques des agonistes des récepteurs au GLP-1 pour le traitement du diabète de type 2. <b>2013</b> , 7, 331-339	3

353	Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?. <b>2013</b> , 24, 207-12	35
352	Successful Primary Care Management of Type II DiabetesContents. <b>2013</b> , 4-111	
351	New incretin hormonal therapies in humans relevant to diabetic cats. <b>2013</b> , 43, 417-33	4
350	Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus. <b>2013</b> , 112, 144-50	12
349	Advances in pharmacologic therapies for type 2 diabetes. <b>2013</b> , 15, 302	13
348	Review article: a comparison of glucagon-like peptides 1 and 2. <b>2013</b> , 37, 18-36	75
347	Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial. <b>2013</b> , 30, 109-13	25
346	A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. <b>2013</b> , 15, 213-23	43
345	Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6). <b>2013</b> , 15, 234-40	16
344	Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. <b>2013</b> , 65, 782-99	119
343	Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. <b>2013</b> , 15, 14-33	251
342	Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. <b>2013</b> , 11, 77-86	69
341	Diabetes Mellitus: New Challenges and Innovative Therapies. <b>2013</b> , 29-87	3
340	Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. <b>2013</b> , 5, 241-53	8
339	The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. <b>2013</b> , 13, 307-18	20
338	Reducing the risk of obesity: defining the role of weight loss drugs. <b>2013</b> , 33, 1308-21	11
337	Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. <b>2013</b> , 15, 593-606	38
336	Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus. <b>2013</b> , 6, 603-12	3

335	Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. <b>2013</b> , 18, 141-8		27
334	Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. <i>Endocrine Practice</i> , <b>2013</b> , 19, 718-28	3.2	7
333	Parkinson's disease, insulin resistance and novel agents of neuroprotection. <b>2013</b> , 136, 374-84		180
332	Role of secretin peptide family and their receptors in the hypothalamic control of energy homeostasis. <b>2013</b> , 45, 945-54		5
331	GLP-1 receptor agonists in the treatment of Type 2 diabetes. <i>Diabetes Management</i> , <b>2013</b> , 3, 401-413	0	12
330	Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach. <b>2013</b> , 125, 112-26		9
329	Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. <b>2013</b> , 3,		207
328	Medicinal chemistry of glucagon-like peptide receptor agonists. <b>2013</b> , 52, 45-96		9
327	Exenatide extended-release; clinical trials, patient preference, and economic considerations. <b>2013</b> , 7, 35-45		6
326	Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. <i>Diabetes Care</i> , <b>2013</b> , 36, 2508-15	14.6	375
325	Non-insulin treatments for diabetes. <b>2013</b> , 20, 377-84		2
324	Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. <b>2013</b> , 20, 638-53		8
323	Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. <b>2013</b> , 10, 72-7		51
322	Glucagon-like peptide-1 analogues: An overview. <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2013</b> , 17, 413-21	1.7	86
321	Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. <b>2013</b> , 15, 463-73		376
320	Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. <b>2013</b> , 4, 53-61		66
319	Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension. <b>2013</b> , 21, 8-24		155
318	Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). <i>Diabetes Care</i> , <b>2013</b> , 36, 2945-51	14.6	193

317	Evolution of Exenatide as a Diabetes Therapeutic. <b>2013</b> , 9, 161-193		2
316	Obesity pharmacotherapy: current perspectives and future directions. <b>2013</b> , 9, 33-54		12
315	Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. <b>2013</b> , 28, 262-74		35
314	Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2013</b> , 6, 31-41	3-4	24
313	Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2013</b> , 6, 171-85	3-4	6
312	Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2r(hull) mice treated with alogliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2013</b> , 6, 493-9	3-4	14
311	Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. <b>2013</b> , 19, 237-46		30
310	Anti-hyperlipidemic activity of <i>Rhynchosia nulubilis</i> seeds pickled with brown rice vinegar in mice fed a high-fat diet. <b>2013</b> , 7, 453-9		8
309	Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e76172	3-7	14
308	Long-acting preparations of exenatide. <i>Drug Design, Development and Therapy</i> , <b>2013</b> , 7, 963-70	4-4	19
307	Evolution of exenatide as a diabetes therapeutic. <b>2013</b> , 9, 161-93		45
306	Pharmacological Treatments for Type 2 Diabetes. <b>2013</b> ,		0
305	Xanthene derivatives increase glucose utilization through activation of LKB1-dependent AMP-activated protein kinase. <i>PLoS ONE</i> , <b>2014</b> , 9, e108771	3-7	5
304	A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. <b>2014</b> , 201, 650-3		42
303	Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. <b>2014</b> , 3, 595-613		7
302	The treatment of type 2 diabetes. <b>2014</b> , 111, 69-81; quiz 82		46
301	A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and $\beta$ Cell Growth. <b>2014</b> , 29, 320-7		10
300	Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors. <b>2014</b> , 05,		1

299	Exendin-4 effects on islet volume and number in the mouse pancreas. <b>2014</b> , 115, 502-7		0
298	Adverse Effects of GLP-1 Receptor Agonists. <i>Review of Diabetic Studies</i> , <b>2014</b> , 11, 202-30	3.6	119
297	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes. <b>2014</b> , 42, 96-108		6
296	The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice. <b>2014</b> , 46, 675-81		3
295	Clinical and laboratory characteristics of exenatide-given patients in endocrinology clinic of a university hospital. <b>2014</b> , 41, 128-132		1
294	Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes (Teil 2). <b>2014</b> , 9, 241-299		1
293	Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic. <b>2014</b> , 44, 345-53		3
292	Early therapy for type 2 diabetes in China. <b>2014</b> , 2, 992-1002		42
291	The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. <b>2014</b> , 16, 673-88		76
290	Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. <b>2014</b> , 16, 900-9		112
289	Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial. <b>2014</b> , 16, 510-8		10
288	Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus. <b>2014</b> , 95, 195-222		6
287	Synthesis of evidence for reimbursement decisions: a Bayesian reanalysis. <b>2014</b> , 30, 438-45		
286	Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists. <b>2014</b> , 32, 32-43		5
285	Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease. <b>2014</b> , 9, 641-658		1
284	Evidence-based practice use of incretin-based therapy in the natural history of diabetes. <b>2014</b> , 126, 66-84		9
283	Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes. <b>2014</b> , 9, 659-670		12
282	Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. <b>2014</b> , 126, 60-72		20

281	The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. <b>2014</b> , 16, 9-21	87
280	Use of exenatide and liraglutide in Denmark: a drug utilization study. <b>2014</b> , 70, 205-14	9
279	New developments in diabetes management: medications of the 21st century. <b>2014</b> , 36, 477-84	22
278	Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption. <b>2014</b> , 231, 3729-44	6
277	Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. <b>2014</b> , 74, 325-51	37
276	Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach. <b>2014</b> , 5, 333-40	6
275	Fiches cliniques. <b>2014</b> , 407-413	
274	Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. <b>2014</b> , 27, 130-9	94
273	Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions. <b>2014</b> , 37, 903-19	19
272	Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes. <b>2014</b> , 5, 554-62	14
271	Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. <b>2014</b> , 31, 861-72	14
270	Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. <b>2014</b> , 34, 237-60	59
269	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. <b>2014</b> , 16, 1016-27	180
268	[Effects of GLP-1 receptor agonists on carbohydrate metabolism control]. <b>2014</b> , 143 Suppl 2, 18-22	
267	[Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy]. <b>2014</b> , 143 Suppl 2, 23-7	
266	Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus. <b>2014</b> , 88, 664-9	18
265	The gut-brain axis in obesity. <b>2014</b> , 28, 559-71	45
264	The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus. <b>2014</b> , 4, S9-S13	11

263	[Safety and tolerability of GLP-1 receptor agonists]. <b>2014</b> , 143 Suppl 2, 35-40	1
262	GLP-1R activation for the treatment of stroke: updating and future perspectives. <b>2014</b> , 15, 233-42	17
261	Extra-pancreatic effects of incretin-based therapies. <b>2014</b> , 47, 360-71	26
260	Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. <b>2014</b> , 221, T1-16	141
259	A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. <b>2014</b> , 22, 403-10	16
258	Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). <b>2014</b> , 28, 386-92	90
257	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. <b>2014</b> , 25, 407-14	101
256	Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. <b>2014</b> , 129, 2305-12	30
255	New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?. <b>2014</b> , 23, 997-1008	8
254	Calcium/calmodulin-dependent serine protein kinase is involved in exendin-4-induced insulin secretion in INS-1 cells. <b>2014</b> , 63, 120-6	19
253	Thérapeutique des troubles glycémiques. <b>2014</b> , 115-188	
252	Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes. <b>2014</b> , 61, 365-72	7
251	Improved human islet preparations using glucocorticoid and exendin-4. <b>2014</b> , 43, 1317-22	6
250	Exenatide enhances INS-1 rat pancreatic $\beta$ cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein. <b>2014</b> , 10, 2447-52	3
249	Implications of incretin-based therapies on cardiovascular disease. <b>2015</b> , 69, 531-49	10
248	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan 2015. <i>Endocrine Practice</i> , <b>2015</b> , 21, 1-87	3,2 390
247	Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial. <b>2015</b> , 14, 48	7
246	Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis. <b>2015</b> , 32, 1530-40	33



245	Characterization of Patients with Type 2 Diabetes according to Body Mass Index: Korea National Health and Nutrition Examination Survey from 2007 to 2011. <b>2015</b> , 30, 514-21		13
244	Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. <b>2015</b> , 3, e1461		28
243	The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126769	3.7	102
242	Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes. <b>2015</b> ,		1
241	Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus. <b>2015</b> , 2015, 162718		19
240	3 Medical Management of Obesity. <b>2015</b> , 15-38		
239	Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. <b>2015</b> , 6, 109-34		33
238	Causal inference methods to assess safety upper bounds in randomized trials with noncompliance. <b>2015</b> , 12, 265-75		
237	Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. <b>2015</b> , 6, 3-18		33
236	Potential side effects to GLP-1 agonists: understanding their safety and tolerability. <b>2015</b> , 14, 207-18		28
235	Welcome reassurance about GLP-1 drugs—but they are still young and not fully grown. <i>Diabetes Care</i> , <b>2015</b> , 38, 183-5	14.6	
234	Incretin-based therapies for obesity treatment. <b>2015</b> , 64, 967-81		21
233	Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis. <b>2015</b> , 109, 451-60		12
232	Clinical implications of canagliflozin treatment in patients with type 2 diabetes. <b>2015</b> , 33, 5-13		5
231	Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. <b>2015</b> , 17, 689-98		3
230	Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. <b>2015</b> , 6, 61-74		19
229	Pharmacologic treatment of type 2 diabetes: injectable medications. <b>2015</b> , 49, 700-14		19
228	Cardiometabolic Effects of a New Class of Antidiabetic Agents. <b>2015</b> , 37, 1178-94		30

227	Drug interactions are an important issue in type 2 diabetes. <b>2015</b> , 31, 350-354		
226	Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy. <b>2015</b> , 127, 827-41		10
225	Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers. <b>2015</b> , 32, 650-61		1
224	The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial. <b>2016</b> , 65, 269-75		42
223	GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice. <b>2015</b> , 41, 32S-46S		8
222	Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. <b>2015</b> , 6, 239-56		64
221	Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin+ Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study. <b>2015</b> , 47, 895-900		10
220	Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. <b>2015</b> , 17, 179-87		68
219	Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective. <b>2015</b> , 17, 335-42		9
218	Incretin-based therapies. <b>2015</b> , 99, 107-29		22
217	A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes. <i>Journal of King Abdulaziz University, Islamic Economics</i> , <b>2016</b> , 37, 834-42	1.1	5
216	Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding. <b>2016</b> , 6, 243-53		44
215	Exenatide. <b>2016</b> , 214-219		
214	Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women. <b>2016</b> , 2016, 1309502		5
213	Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. <b>2016</b> , 2016, 6962574		5
212	The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review. <b>2016</b> , 13,		2
211	Exenatide Treatment Alone Improves $\beta$ Cell Function in a Canine Model of Pre-Diabetes. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158703	3.7	2
210	Update on the treatment of type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , <b>2016</b> , 7, 354-95	4.7	269

209	The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. <b>2016</b> , 82, 301-14	19
208	Non-Insulin Parenteral Therapies. <b>2016</b> , 455-470	
207	DLBS3233, a combined bioactive fraction of <i>Cinnamomum burmanii</i> and <i>Lagerstroemia speciosa</i> , in type-2 diabetes mellitus patients inadequately controlled by metformin and other oral antidiabetic agents. <b>2016</b> , 13, 413-420	3
206	Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. <b>2016</b> , 16, 44	11
205	Triple therapy combinations for the treatment of type 2 diabetes - A network meta-analysis. <b>2016</b> , 116, 149-58	23
204	Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon. <b>2016</b> , 326, 279-341	11
203	Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials. <b>2016</b> , 219, 293-300	12
202	Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials. <b>2016</b> , 70, 649-56	9
201	Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 µg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis. <b>2016</b> , 8, 866-876	4
200	Targeting the gastrointestinal tract to treat type 2 diabetes. <b>2016</b> , 230, R95-R113	18
199	Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. <b>2016</b> , 121, 27-34	22
198	Molecular regulation of insulin granule biogenesis and exocytosis. <b>2016</b> , 473, 2737-56	14
197	A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. <b>2016</b> , 8, 341ra76	77
196	Dulaglutid: GLP-1-Rezeptoragonist zur einmal wohentlichen Therapie des Typ-2-Diabetes. <b>2016</b> , 11, 398-417	1
195	Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis. <b>2016</b> , 17, 1591-8	2
194	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. <b>2016</b> , 12, 566-92	205
193	Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial. <b>2016</b> , 17, 160	5
192	Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation. <b>2016</b> , 104, 52-61	31

191	Computational insight into conformational states of glucagon-like peptide-1 receptor (GLP-1R) and its binding mode with GLP-1. <b>2016</b> , 6, 13490-13497	5
190	Pancreatic regulation of glucose homeostasis. <b>2016</b> , 48, e219	317
189	Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. <b>2016</b> , 11, 281-296	
188	A systematic review of the safety of incretin-based therapies in type 2 diabetes. <b>2016</b> , 11, 217-232	4
187	[Type 2 diabetes--criteria for the selection of the antidiabetic drug]. <b>2016</b> , 141, 285-8	0
186	Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis. <b>2016</b> , 114, 160-72	11
185	Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. <b>2016</b> , 32, 807-16	24
184	Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea. <b>2016</b> , 153, 109-14	16
183	Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink. <b>2016</b> , 32, 49-60	7
182	Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. <b>2016</b> , 9, 241-65	16
181	Dapagliflozin combination therapy in type 2 diabetes mellitus. <b>2016</b> , 128, 124-36	2
180	The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. <b>2016</b> , 32, 61-76	20
179	Role of gastrointestinal hormones in feeding behavior and obesity treatment. <b>2016</b> , 51, 93-103	16
178	Type 2 Diabetes. <b>2016</b> ,	2
177	Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds. <b>2017</b> , 57, 52-63	3
176	Exenatide: pharmacokinetics, clinical use, and future directions. <b>2017</b> , 18, 555-571	39
175	The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. <b>2017</b> , 34, 638-657	3
174	Sarcoplasmic reticulum-mitochondria communication in cardiovascular pathophysiology. <b>2017</b> , 14, 342-360	80

173	Glucagon-like peptide-1 agonists for weight loss in people with obesity. <b>2017</b> , 5, 29-43	
172	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. <b>2017</b> , 19, 25	1
171	Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. <b>2017</b> , 19, 1339-1352	28
170	The effects of GLP-1 analogues on pre-diabetes of the children. <b>2017</b> , 13, 1426-1430	5
169	Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea. <b>2017</b> , 65, 28-36	6
168	Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. <b>2017</b> , 39, 1244-1264	9
167	WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. <b>2017</b> ,	1
166	Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration. <b>2017</b> , 19, 487-496	11
165	Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. <b>2017</b> , 19, 524-536	216
164	Rezeptoragonisten des $\beta$ glucagon-like peptide 1 <b>2017</b> , 13, 487-497	
163	Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. <b>2017</b> , 41, 524-535	40
162	Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes. <b>2017</b> , 14, 3954-3967	18
161	Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. <b>2017</b> , 8, 1175-1185	3
160	Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c $\geq$ 10.0%: Two pooled analyses including 20 randomised controlled trials. <b>2017</b> , 71, e13029	3
159	Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors. <b>2017</b> , 32, 165-182	9
158	Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. <b>2017</b> , 37, 1107-1115	2
157	Misunderstandings and controversies about the insulin-secreting properties of antidiabetic sulfonylureas. <b>2017</b> , 143, 3-9	9
156	The Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes. <b>2017</b> , 5, 79-89	6

155	Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus. <b>2017</b> , 125, 419-435		6
154	Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice. <b>2017</b> , 362, 441-449		5
153	Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146. <b>2017</b> , 281, 25-40		20
152	Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus. <b>2017</b> , 11, 225-230		19
151	Population pharmacokinetics of exenatide. <b>2017</b> , 83, 517-526		13
150	Cardiovascular safety of therapies for type 2 diabetes. <b>2017</b> , 16, 13-25		5
149	RhGLP-1 (7-36) protects diabetic rats against cerebral ischemia-reperfusion injury via up-regulating expression of Nrf2/HO-1 and increasing the activities of SOD. <b>2017</b> , 21, 475-485		8
148	Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides. <i>Frontiers in Endocrinology</i> , <b>2017</b> , 8, 18	5-7	14
147	Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice. <b>2017</b> , 17, 68		4
146	Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2017</b> , 10, 111-122	3-4	19
145	Japanese Clinical Practice Guideline for Diabetes 2016. <b>2018</b> , 9, 657		136
144	Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data. <b>2018</b> , 34, 1045-1051		1
143	A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. <b>2018</b> , 20 Suppl 1, 22-33		118
142	Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus. <b>2018</b> , 7, 193-198		2
141	Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. <b>2018</b> , 14, 207-217		6
140	A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents. <b>2018</b> , 20, 1223-1234		18
139	Glucagon-like peptide 1 in health and disease. <b>2018</b> , 14, 390-403		187
138	Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin. <b>2018</b> , 20, 638-645		4

137	Anti-diabetic potential of peptides: Future prospects as therapeutic agents. <b>2018</b> , 193, 153-158	29
136	Pharmacotherapy of type 2 diabetes: An update. <b>2018</b> , 78, 13-42	103
135	The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197407	3-7 5
134	Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy. <b>2018</b> , 141, 2925-2942	17
133	Japanese Clinical Practice Guideline for Diabetes 2016. <b>2018</b> , 9, 1-45	114
132	Clinical pharmacology of glucagon-like peptide-1 receptor agonists. <b>2018</b> , 17, 333-350	26
131	Effect of miR-19b on the protective effect of Exendin-4 on islet cells in non-obese diabetic mice. <b>2019</b> , 18, 503-508	5
130	Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes. <b>2019</b> , 8,	12
129	Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output. <b>2019</b> , 41, 73-84	22
128	The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <b>2019</b> , 2019, 8083417	0
127	Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. <b>2019</b> , 35, e3070	104
126	Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients. <b>2019</b> , 11, 509-518	8
125	Incretins in obesity and diabetes. <b>2020</b> , 1461, 104-126	32
124	Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties. <b>2020</b> , 95, 103538	5
123	The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. <b>2020</b> , 103, 154031	3
122	Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis. <b>2020</b> , 31, 107768	9
121	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. <b>2020</b> , 18, 322	1
120	Japanese Clinical Practice Guideline for Diabetes 2019. <b>2020</b> , 11, 1020-1076	46

119	Japanese Clinical Practice Guideline for Diabetes 2019. <b>2020</b> , 11, 165-223	75
118	Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention. <b>2020</b> , 34, 107619	7
117	A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models. <b>2020</b> , 22, 1729-1741	6
116	GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis. <b>2020</b> , 30, 3561-3569	1
115	Acupuncture for patients with glucagon-like peptide-1 receptor agonists-induced nausea and vomiting: A systematic review protocol. <b>2020</b> , 99, e20343	
114	Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial. <b>2020</b> , 57, 991-1000	2
113	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. <b>2020</b> , 8, 313-324	18
112	Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus. <b>2021</b> , 126, 567-571	0
111	Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4. <b>2021</b> , 64, 3479-3492	1
110	The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. <b>2021</b> , 38, 355-373	2
109	The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. <b>2022</b> , 34, 104-111	
108	The Role of GIP in the Regulation of GLP-1 Satiety and Nausea. <b>2021</b> , 70, 1956-1961	5
107	A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats. <b>2021</b> , 192, 108599	2
106	DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity. <b>2021</b> , 278, 119574	2
105	Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. <b>2021</b> ,	3
104	Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes. <b>2021</b> , 30, 233-247	1
103	Glycaemic variabilities: Key questions in pursuit of clarity. <b>2021</b> , 47, 101283	3
102	Vernicia fordii (Hemsl.) Airy Shaw extract stimulates insulin secretion in pancreatic $\beta$ cells and improves insulin sensitivity in diabetic mice. <b>2021</b> , 278, 114238	



101	The Role of Incretins in Insulin Secretion. <b>2010</b> , 57-74		1
100	Treating Type 2 Diabetes Mellitus. <b>2010</b> , 731-747		1
99	Management and treatment of diabetes mellitus. <b>2012</b> , 771, 356-80		16
98	The Transition from Oral Agents to Combination Insulin/Oral Therapy. <b>2008</b> , 169-181		3
97	Environmental Inputs, Intake of Nutrients, and Endogenous Molecules Contributing to the Regulation of Energy Homeostasis. <b>2009</b> , 41-75		1
96	GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. <b>2011</b> , 53-74		26
95	Incretins and Regulation of Insulin Secretion. <b>2008</b> , 335-378		4
94	DIABETES MELLITUS. <b>2009</b> , 557-570		1
93	Glycemic Management. <i>Endocrine Practice</i> , <b>2007</b> , 13, 16-34	3.2	3
92	Bowels control brain: gut hormones and obesity. <b>2012</b> , 22, 283-97		16
91	The role of gut hormones in glucose homeostasis. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 24-32	15.9	436
90	Beta cell transplantation and immunosuppression: can't live with it, can't live without it. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 2380-2	15.9	6
89	Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. <i>PLoS ONE</i> , <b>2013</b> , 8, e78154	3.7	29
88	Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154206	3.7	18
87	A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154727	3.7	7
86	Heterologous Expression and Delivery of Biologically Active Exendin-4 by <i>Lactobacillus paracasei</i> L14. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165130	3.7	8
85	Significance of the results of genome-wide association studies for primary prevention of type 2 diabetes mellitus and its complications. Personalised approach. <i>Diabetes Mellitus</i> , <b>2014</b> , 17, 10-19	1.6	5
84	Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity. <i>Obesity and Metabolism</i> , <b>2018</b> , 15, 22-30	0.6	4

83	Exendin-4 effects on islet volume and number in mouse pancreas. <i>Brazilian Journal of Pharmaceutical Sciences</i> , <b>2013</b> , 49, 745-752	1.8	1
82	New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. <i>Review of Diabetic Studies</i> , <b>2005</b> , 2, 61-9	3.6	29
81	Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. <i>Review of Diabetic Studies</i> , <b>2008</b> , 5, 73-94	3.6	82
80	Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists. <i>Review of Diabetic Studies</i> , <b>2009</b> , 6, 247-59	3.6	13
79	Incretin therapy--present and future. <i>Review of Diabetic Studies</i> , <b>2011</b> , 8, 307-22	3.6	21
78	The role of incretin therapy at different stages of diabetes. <i>Review of Diabetic Studies</i> , <b>2011</b> , 8, 323-38	3.6	20
77	A review of exenatide as adjunctive therapy in patients with type 2 diabetes. <i>Drug Design, Development and Therapy</i> , <b>2009</b> , 3, 219-40	4.4	31
76	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , 3, 227-42	3.4	8
75	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , 2, 135-44	3.4	2
74	Emerging role of GLP-1 receptor agonists in the treatment of obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , 3, 263-73	3.4	8
73	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , 3, 165-72	3.4	3
72	Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. <i>Vascular Health and Risk Management</i> , <b>2006</b> , 2, 69-77	4.4	23
71	No Superiority of Exenatide over Insulin in Diabetic Patients in Terms of Weight Reduction or Incidence of Adverse Effects: A Meta-analysis. <i>International Journal of Pharmacology</i> , <b>2011</b> , 7, 749-756	0.7	8
70	Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2016</b> , 20, 254-67	1.7	44
69	Pleiotropic effects of incretins. <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2012</b> , 16 Suppl 1, S47-56	1.7	24
68	Cystic fibrosis-related diabetes mellitus: etiology, evaluation, and management. <i>Endocrine Practice</i> , <b>2008</b> , 14, 1169-79	3.2	6
67	Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , <b>2008</b> , 14, 285-292	3.2	10
66	Obesity and type 2 diabetes. <i>Journal of Diabetes Mellitus</i> , <b>2011</b> , 01, 79-95	0.5	28

65	Exenatide efficacy in unselected patients: Comparison with clinical trials. <i>Journal of Diabetes Mellitus</i> , <b>2012</b> , 02, 118-121	0.5	2
64	Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?. <i>Open Journal of Endocrine and Metabolic Diseases</i> , <b>2016</b> , 06, 43-57	0.1	1
63	Pleiotropic Effects of GLP-1. Cardiovascular Evidence of Effectiveness. <i>Pharmacology &amp; Pharmacy</i> , <b>2013</b> , 04, 647-650	0.3	2
62	Comparison of awareness of diabetes mellitus type II with treatment's outcome in term of direct cost in a hospital in Saudi Arabia. <i>World Journal of Diabetes</i> , <b>2019</b> , 10, 463-472	4.7	4
61	Pharmacological Treatment of the Overweight Patient. <b>2007</b> , 203-256		1
60	The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors). <b>2007</b> , 111-141		
59	Sovremennye vozmozhnosti farmakoterapii sakharnogo diabeta 2 tipa pri pomoshchi analogov glyukagonopodobnogo peptida-1 (GPP-1). <i>Diabetes Mellitus</i> , <b>2007</b> , 10, 9-15	1.6	1
58	Introduction. <i>Endocrine Practice</i> , <b>2007</b> , 13, 4-9	3.2	18
57	Treatment Strategies for Type 2 Diabetes Based on Incretin Action. <b>2007</b> , 159-169		1
56	Combination Therapy for Treatment of Type 2 Diabetes. <b>2007</b> , 207-226		
55	Neue Arzneimittel 2007. <b>2008</b> , 47-118		
54	Exenatid. <b>2008</b> , 29,		
53	Postprandial Hyperglycemia. <b>2008</b> , 97-113		
52	Type 2 Diabetes and Concomitant Illness. <b>2008</b> , 203-233		
51	Vybor taktiki lecheniya u patsientov s neudovletvoritel'noy kompensatsiey sakharnogo diabeta 2 tipa: vozmozhnosti naznacheniya mimitika inkretinov eksenatida (na primere klinicheskogo sluchaya). <i>Diabetes Mellitus</i> , <b>2008</b> , 11, 84-88	1.6	
50	INSULINS AND OTHER HYPOGLYCEMIC DRUGS. <b>2009</b> , 357-473		
49	Glucagon and the Glucagon-Like Peptides. <b>2010</b> , 660-672		
48	Fiches cliniques. <b>2010</b> , 397-404		

- 47 Thérapeutique des troubles glycémiques. **2010**, 119-174
- 46 Obesity. **2010**, 99-114.e4
- 45 How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 494-513
- 44 Non-Insulin Injectables. **2011**, 153-168
- 43 Pharmacologic Approaches to Type 2 Diabetes and Obesity in Children and Adolescents. **2011**, 275-310
- 42 References. **2011**, 283-360
- 41 Glucagon-like peptide-1 alleviating peripheral neuropathy in diabetic patients: advance in mechanism. *Academic Journal of Second Military Medical University*, **2011**, 31, 329-333
- 40 [Incretin-based therapy for treating patients with type 2 diabetes]. *Orvosi Hetilap*, **2011**, 152, 1931-40 0.8 1
- 39 Efficacy of GLP-1 analog to achieve metabolic control and correction of body weight in patients with type 2 diabetes mellitus. *Bulletin of Siberian Medicine*, **2011**, 10, 114-119 0.4
- 38 Introduction. *SpringerBriefs in Pharmaceutical Science & Drug Development*, **2013**, 1-13 0
- 37 The collateral benefits of noninsulin therapies for Type 2 diabetes. *Diabetes Management*, **2013**, 3, 145-160
- 36 Glucagon-Like Peptide-1 (GLP-1) Agonist. *Korean Journal of Medicine*, **2014**, 87, 9 0.5
- 35 The Role of Incretins in Insulin Secretion. **2016**, 1-13
- 34 The Role of Incretins in Insulin Secretion. **2017**, 57-69
- 33 Glucagon like peptide 1 receptor agonists: a therapy for diabetes management. **2018**, 32, 23-30
- 32 Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity.. *Klinicheskaia Meditsina*, **2018**, 96, 746-753 0.2
- 31 Fiches cliniques. **2019**, 541-557
- 30 Thérapeutique des troubles glycémiques. **2019**, 141-252

29	A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y receptors. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2021</b> , 131, 1169-1179 <sup>9</sup>		2
28	Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus. <b>2021</b> , 187-197		
27	Incretin-Based Therapy for the Management of Type 2 Diabetes. <b>2021</b> , 146-160		
26	Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. <b>2006</b> , 113-143		
25	Coming of Age for the Incretins. <b>2008</b> , 269-290		
24	The burden of type 2 diabetes: strategies to prevent or delay onset. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 511-20	4.4	13
23	Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. <i>Medscape Journal of Medicine</i> , <b>2008</b> , 10, 171		34
22	Role and development of GLP-1 receptor agonists in the management of diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , 2, 37	3.4	2
21	Incretin agents in type 2 diabetes. <i>Canadian Family Physician</i> , <b>2010</b> , 56, 639-48	0.9	30
20	Tackling obesity: new therapeutic agents for assisted weight loss. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , 3, 95-112	3.4	3
19	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , 3, 155-63	3.4	10
18	Diabetes: glycaemic control in type 2 (drug treatments). <i>Clinical Evidence</i> , <b>2012</b> , 2012,		6
17	Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. <i>Open Medicine</i> , <b>2012</b> , 6, e62-74		14
16	Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications. <i>Pharmacy Practice</i> , <b>2006</b> , 4, 129-33	1.8	3
15	Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus. <i>GMS German Medical Science</i> , <b>2014</b> , 12, Doc14	3.2	2
14	Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes. <i>Journal of King Abdulaziz University, Islamic Economics</i> , <b>2014</b> , 35, 1404-7	1.1	
13	Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 108044	13.9	1
12	Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. <i>EClinicalMedicine</i> , <b>2021</b> , 42, 101213	11.3	5

11	The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism.. <i>Frontiers in Endocrinology</i> , <b>2022</b> , 13, 863184	5.7	0
10	Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.. <i>Frontiers in Endocrinology</i> , <b>2022</b> , 13, 838410	5.7	2
9	Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research.. <i>Frontiers in Neurology</i> , <b>2022</b> , 13, 844697	4.1	2
8	Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.. <i>Cureus</i> , <b>2022</b> , 14, e23554	1.2	
7	Crosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases.. <i>Peptides</i> , <b>2022</b> , 170834	3.8	0
6	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. <b>2022</b> ,		8
5	Glucose-Responsive Nanochaperones Mediate Exendin-4 Delivery for Enhancing Therapeutic Effects. <b>2022</b> , 14, 44211-44221		0
4	Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. <b>2022</b> , 100456		0
3	Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use. <b>2022</b> , 12, 1915		0
2	GLP-1R Signaling and Functional Molecules in Incretin Therapy. <b>2023</b> , 28, 751		0
1	Short-term effect of polyethylene glycol loxanatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. 14,		0